Proteomic approach for molecular understanding of lung cancer in never smoker.
- 주제(키워드) never-smoker lung cancer , Proteomics , biomarker
- 발행기관 고려대학교 대학원
- 지도교수 박윤규
- 발행년도 2011
- 학위수여년월 2011. 8
- 학위구분 석사
- 학과 일반대학원 의학과
- 세부전공 분자.세포.발생.생물학 전공
- 원문페이지 51 p
- 실제URI http://www.dcollection.net/handler/korea/000000027014
- 본문언어 영어
- 제출원본 000045667841
초록/요약
On a worldwide level, lung cancer in never-smokers (LCINS) occupies 25% of total lung cancer incidence and this disease shows the 7th leading cause of cancer death. It is known that LCINS occurs frequently in asian women. It has been reported that LCINS occupied 75% of female lung cancer occurred in Republic of Korea. There are the clinico-pathological and molecular differences as well as geographic and gender variations between lung cancers in never-smokers and smokers, indicating that two types of lung cancers should be regarded as a different disease entity. However, data for molecular understanding of LCINS are limited. This study was designed to identify the proteins differentially expressed in LCINS through proteomic analysis including 2-DE and MALDI-TOF-MS. To increase the probability of finding LCINS-associated proteins, the serum specimens were classified as the following: normal female smokers, normal female never-smokers, lung cancer in female smokers, and lung cancer in female never-smokers. In the case of tissues, cancer tissue and corresponding normal tissues of the female never-smokers with lung cancer were used. The 16 proteins were detected only in serum of the female never-smokers with lung cancer, and 6 proteins among them were identified. Among these proteins, gelsolin and cortactin were verified by Western blot analysis and ELISA, respectively. Out of the proteins differentially expressed in tissues of the female never-smokers with lung cancer levels of 12 proteins were increased and those of 8 proteins were decreased. Among these proteins, 5 proteins were verified not only in the same tissues used for 2-DE but also in non-small lung cancer cell lines. In addition, these seven proteins were verified in in vitro lung carcinogenesis model. Seven verified proteins might be applicable to biomarker development for diagnosis of LCINS and provide a more comprehensive understanding of tumor maintenance and progression.
more목차
CONTENTS
Abstract ⅰ
Introduction 1
Materials and Methods 4
1. Cell culture 4
2. Preparation of clinical specimens 5
3. Two-dimensional electrophoresis (2-DE) 8
4. Image acquisition and data analysis 8
5. Protein identification 9
6. Western blot analysis 9
7. Enzyme-linked immunosorbent assay (ELISA) 10
Results 11
1. 2-DE profiling of clinical specimens 11
2. Identification of differentially expressed proteins 16
3. Validation of differentially expressed proteins in clinical specimens 26
4. Validation of differentially expressed proteins using lung cancer cell lines 31
Discussion 34
국문요약 39
References 41
